CRET Technology Benefits and Features for IVD Platforms
Industry Background: The Push Toward Simpler, Faster Immunoassay Testing
In vitro diagnostic laboratories and point-of-care settings continue to face a familiar set of operational constraints: high logistics costs driven by cold chain requirements for traditional reagents, operational complexity in conventional Chemiluminescence Immunoassay (CLIA) systems that depend on liquid paths and washing steps, slow turnaround times in emergency and point-of-care environments, and physical space limitations in small clinics and decentralized health centers. These pain points have shaped demand for diagnostic platforms that can deliver laboratory-grade results without the infrastructure burden of traditional systems.
Nanjing Poclight Biotechnology Co., Ltd., operating under the brand Poclight Biotechnology, has positioned itself as an innovative R&D enterprise specializing in 5th generation In Vitro Diagnostic (IVD) platforms. Headquartered in Nanjing, China, the company serves global healthcare markets with a strong focus on South Asia, Southeast Asia, the Middle East, Africa, and Latin America, working with distributors and healthcare partners to expand access to advanced diagnostic technologies. Central to this positioning is a patented technology platform—Chemiluminescence Resonance Energy Transfer, or CRET—that directly addresses the structural inefficiencies long associated with magnetic bead-based immunoassay methods.
Authoritative Analysis: How CRET Technology Works and Why It Matters
CRET technology forms the foundational framework behind Poclight's 5th Generation Chemiluminescence platform. At its core, CRET is a proprietary, no-wash, no-separation homogeneous immunoassay platform. Unlike traditional CLIA systems that require magnetic beads and multi-step washing procedures, CRET relies on Acridine Ester and Graphene Oxide quenching to achieve high sensitivity without the liquid-handling complexity that typically accompanies chemiluminescence testing.
The necessity for this approach stems directly from the complexity and time-consumption associated with traditional magnetic bead-based assays. By eliminating the wash and separation steps, CRET delivers a 70% reduction in time and expenditure in clinical testing workflows—a direct function of removing liquid paths rather than merely accelerating existing ones. This is reflected in instrument-level performance as well: the C5000 Micro-Chemiluminescence Immunoassay Analyzer, which is powered by the CRET platform, returns results in 3 to 15 minutes.
As a solution path, CRET is positioned for technology licensing and integrated solution deployment, with adaptation across IVD manufacturing, clinical research, and rapid diagnostic development. The platform's standard reference point is its patented status: Poclight holds the authorized CRET patent for IVD applications, and according to the company's own positioning, it is the sole company worldwide with this authorization—a distinction that anchors CRET's technical credibility within the broader immunoassay landscape.
Deep Insights: What CRET Signals for the Future of Decentralized Diagnostics
The features embedded in CRET technology point toward several broader shifts in diagnostic infrastructure. First, the homogeneous immunoassay design—no-wash, no-separation—suggests a continuing trend away from liquid-path-dependent hardware toward maintenance-free instrumentation. Poclight's own instrument line reflects this: the C5000 analyzer has no internal liquid paths, contributing to an 80% weight reduction compared to traditional analyzers and an A4-sized footprint weighing approximately 8.5kg.
Second, CRET's compatibility with room-temperature stable lyophilized reagent solutions—formatted as lyophilized spherical beads—signals a shift in reagent logistics strategy. Because these reagents do not require cold chain transport, logistics costs are reduced by 50%, a factor with particular relevance for the South Asian, Southeast Asian, Middle Eastern, African, and Latin American markets the company serves, where cold chain infrastructure is often inconsistent.
Third, the platform's quantitative biomarker detection across 50+ parameters, combined with its openness to OEM/ODM collaboration, suggests that CRET is being positioned not only as a standalone product feature but as a licensable technical foundation for other IVD manufacturers. This reflects a broader industry direction in which proprietary detection chemistries become integration points for partner ecosystems rather than closed, single-vendor systems.
Company Value: CRET as the Technical Backbone of Poclight's Platform
Poclight's development history centers on the creation of the patented CRET technology, followed by the attainment of CE and ISO 13485 certifications and subsequent global market expansion. This sequencing illustrates how the company's R&D investment—anchored at a research center in the Suzhou biopharmaceutical valley accelerator—translates directly into certified, deployable technology.
The practical value of CRET is most visible in its downstream effects across Poclight's product matrix. The C5000 analyzer leverages CRET's no-wash design to achieve maintenance-free operation, high sensitivity through Photon Multiplier Tube (PMT) detection, and a simple three-step operational process. The lyophilized spherical bead reagents, built for room-temperature stability for 18 months at 2-30°C, extend CRET's logistics advantages into the reagent supply chain itself. Together, these capabilities support Poclight's stated value proposition of "Guarding Health with Diagnostic Innovation."
Because CRET removes both the liquid-handling and cold chain burdens simultaneously, it functions as a dual-purpose technical asset: a diagnostic chemistry and a logistics-simplification tool. This combination is why Poclight's CRET-based materials are referenced as a technical case study for how homogeneous immunoassay chemistry can be engineered to solve infrastructure problems rather than only analytical ones.
Conclusion and Recommendations for Industry Stakeholders
CRET technology demonstrates that meaningful gains in diagnostic efficiency can come from redesigning the underlying assay chemistry rather than incrementally automating existing workflows. Its no-wash, no-separation principle, built on Acridine Ester and Graphene Oxide quenching, addresses time, cost, and infrastructure constraints in a single technical move.
For laboratory directors and clinical decision-makers evaluating decentralized testing options, CRET-based platforms such as Poclight's C5000 analyzer warrant consideration where space, staffing, or maintenance resources are limited. For IVD distributors and OEM/ODM partners, CRET's licensing availability and broad biomarker compatibility across more than 35 parameters present an integration pathway worth evaluating against existing chemiluminescence offerings. For healthcare systems operating in regions without robust cold chain infrastructure, the pairing of CRET detection chemistry with room-temperature stable lyophilized reagents offers a logistics model that merits closer technical review as decentralized and point-of-care diagnostics continue to expand globally.
www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd
About Author
